Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer

Gene Therapy

Volumn 6, Issue 1, 1999, Pages 57-62

  Wildner, O ^a   Morris, J C ^a   Vahanian, N N ^a   Ford Jr , H ^b   Ramsey, W J ^a   Blaese, R M ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cervical cancer; Gancliclovir; Gene therapy; Melanoma; Replication competent adenovirus; Thymidine kinase

Indexed keywords

GANCICLOVIR; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; GENE THERAPY; GENETIC TRANSDUCTION; INTRATUMORAL DRUG ADMINISTRATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUICIDE GENE; SURVIVAL TIME; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; ANTIMETABOLITES; FEMALE; GANCICLOVIR; GENE THERAPY; GENETIC VECTORS; MELANOMA; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; NEOPLASMS, EXPERIMENTAL; SIMPLEXVIRUS; THYMIDINE KINASE; UTERINE CERVICAL NEOPLASMS; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALIA; HERPES; MUS MUSCULUS;

EID: 0032922211     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300810     Document Type: Article

References (43)

1. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986; 46: 5276-5281.
2. Freeman SM et al. The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
3. Takamiya Y et al. Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild-type retrovirus kills other tumor cells. J Neurosci Res 1992; 33: 493-503.
4. Miyatake S, Martuza RL, Rabkin SD. Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma. Cancer Gene Ther 1997; 4: 222-228.
5. Dion LD et al. E1A RNA transcripts amplify adenovirus-mediated tumor reduction. Gene Therapy 1996; 3: 1021-1025.
6. Culver KW et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550-1552.
7. Ram Z et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nature Med 1997; 3: 1354-1361.
8. Norrby E. Viral vaccines: the use of currently available products and future developments. Arch Virol 1983; 76: 163-177.
9. Smith RR et al. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 1956; 9: 1211-1218.
10. Southam CM. Present status of oncolytic virus studies. Trans NY Acad Sci 1960; 22: 657-673.
11. Asada T. Treatment of human cancer with mumps virus. Cancer 1974; 34: 1907-1928.
12. Bischoff JR et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373-376.
13. Freytag SO et al. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther 1998; 9: 1323-1333.
14. Maxfield LF, Spector DJ. Readthrough activation of early adenovirus E1b gene transcription. J Virol 1997; 71: 8321-8329.
15. Larsson S, Svensson C, Akusjarvi G. Control of adenovirus major late gene expression at multiple levels. J Mol Biol 1992; 225: 287-298.
16. Thomas GP, Mathews MB. DNA replication and the early to late transition in adenovirus infection. Cell 1980; 22: 523-533.
17. Barker DD, Berk AJ. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 1987; 156: 107-121.
18. Morgan RA et al. Retroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy. Nucleic Acids Res 1992; 20: 1293-1299.
19. van der Eb AJ, Mulder C, Graham FL, Houweling A. Transformation with specific fragments of adenovirus DNAs. I. Isolation of specific fragments with transforming activity of adenovirus 2 and 5 DNA. Gene 1977; 2: 115-132.
20. Berkner KL, Sharp PA. Effect of the tripartite leader on synthesis of a non-viral protein in an adenovirus 5 recombinant. Nucleic Acids Res 1985; 13: 841-857.
21. Mason BB et al. Adenovirus vaccine vectors expressing hepatitis B surface antigen: importance of regulatory elements in the adenovirus major late intron. Virology 1990; 177: 452-461.
22. Elshami AA et al. The effect of promoter strength in adenoviral vectors containing herpes simplex virus thymidine kinase on cancer gene therapy in vitro and in vivo. Cancer Gene Ther 1997; 4: 213-221.
23. Eloit M, Adam M. Isogenic adenoviruses type 5 expressing or not expressing the E1A gene: efficiency as virus vectors in the vaccination of permissive and non-permissive species. J Gen Virol 1995; 76: 1583-1589.
24. Klein G, Klein E. Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: contrasting consequences of host versus tumor evolution. Proc Natl Acad Sci USA 1977; 74: 2121-2125.
25. Cook JL et al. Expression of the adenovirus E1A oncogene during cell transformation is sufficient to induce susceptibility to lysis by host inflammatory cells. Proc Natl Acad Sci USA 1986; 83: 6965-6969.
26. Bellgrau D, Walker TA, Cook JL. Recognition of adenovirus E1A gene products on immortalized cell surfaces by cytotoxic T lymphocytes. J Virol 1988; 62: 1513-1519.
27. Routes JM et al. Anti-adenovirus type 5 cytotoxic T lymphocytes: immunodominant epitopes are encoded by the E1A gene. J Virol 1991; 65: 1450-1457.
28. Cook JL, Potter TA, Bellgrau D, Routes BA. E1A oncogene expression in target cells induces cytolytic susceptibility at a post-recognition stage in the interaction with killer lymphocytes. Oncogene 1996; 13: 833-842.
29. Bonnekoh B et al. Adenoviral-mediated herpes simplex virus-thymidine kinase gene transfer in vivo for treatment of experimental human melanoma. J Invest Dermatol 1996; 106: 1163-1168.
30. Bett AJ, Haddara W, Prevec L, Graham FL. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA 1994; 91: 8802-8806.
31. Davis AR et al. Expression of hepatitis B surface antigen with a recombinant adenovirus. Proc Natl Acad Sci USA 1985; 82: 7560-7564.
32. Graham FL, Prevec L. Methods for construction of adenovirus vectors. Mol Biotechnol 1995; 3: 207-220.
33. Kroumpouzos G, Eberle J, Garbe C, Orfanos CE. P53 mutation and c-fos overexpression are associated with detection of the antigen VLA-2 in human melanoma cell lines. Pigment Cell Res 1994; 7: 348-353.
34. Reuter S et al. Characterization of a novel human papillomavirus DNA in the cervical carcinoma cell line ME180. J Virol 1991; 65: 5564-5568.
35. Dethlefsen LA, Prewitt JM, Mendelsohn ML. Analysis of tumor growth curves. J Natl Cancer Inst 1968; 40: 389-405.
36. Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 1990; 82: 297-300.
37. Ishii-Morita H et al. Mechanism of 'bystander effect' killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Therapy 1997; 4: 244-251.
38. Onodera M et al. A simple and reliable method for screening retroviral producer clones without selectable markers. Hum Gene Ther 1997; 8: 1189-1194.
39. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual, 2nd edn. Cold Spring Harbor Laboratory Press: Plainview, NY, 1989.
40. Feinberg AP, Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 1983; 132: 6-13.
41. Agbaria R et al. Effects of IMP dehydrogenase inhibitors on the phosphorylation of ganciclovir in MOLT-4 cells before and after herpes simplex virus thymidine kinase gene transduction. Mol Pharmacol 1994; 45: 777-782.
42. Ahluwalia GS, Driscoll JS, Ford HJ, Johns DG. Comparison of the DNA incorporation in human MOLT-4 cells of two 2′-beta-fluoronucleosides, 2′-beta-fluoro-2′,3′-dideoxyadenosine and fialuridine. J Pharm Sci 1996; 85: 454-455.
43. Treisman J et al. Interleukin-2-transduced lymphocytes grow in an autocrine fashion and remain responsive to antigen. Blood 1995; 85: 139-145.